Howard Marks’s CERo Therapeutics CERO Stock Holding History

Howard Marks’s Portfolio CERO Stock Details CERO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100	Closed	-$1.98M	–	371
2021 Q4	$1.98M	Buy	+100	New	+$1.99M	0.02%	240

Other funds holding CERO

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

Howard Marks's CERO Position: Q1 2022 in Review

Howard Marks sold out of CERo Therapeutics (CERO) in Q1 2022, closing a stake of 100 shares — an estimated $1.98M sold.

Howard Marks first reported a position in CERO in Q4 2021 and held it in 1 quarter. The position peaked at $1.98M in Q4 2021. 45 funds tracked by Wall St. Rank hold CERO as of Q1 2022.

Howard Marks reported no remaining CERo Therapeutics position as of Q1 2022 after selling out during the quarter.
Howard Marks sold 100 CERo Therapeutics shares in Q1 2022, an estimated $1.98M.
Howard Marks first reported a position in CERo Therapeutics in Q4 2021 and held it in 1 quarter.
Howard Marks's CERo Therapeutics position peaked at $1.98M in Q4 2021.
45 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2022.

Based on Oaktree Capital Management's 13F filing for Q1 2022, filed 16 May 2022.